{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-000067","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.014530+00:00","generated_at":"2026-05-16T11:34:46.503137+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026","bullets":["SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.","Positive regulatory feedback from Germany's BfArM on Phase 2/3 design; toxicology studies completed.","Phase 2/3 LAPC trial initiation planned H1 2026; US IND expected H2 2026.","Company raised over $18M in 2025 and regained Nasdaq compliance; addressable market >$30B."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-000067","json":"https://secwatch.observer/filing/0001178913-26-000067.json","markdown":"https://secwatch.observer/filing/0001178913-26-000067.md","text":"https://secwatch.observer/filing/0001178913-26-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/0001178913-26-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/zk2634187.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:34:46.503137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}